Sigma Planning Corp Eiger Bio Pharmaceuticals, Inc. Transaction History

Sigma Planning Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 06, 2023	SELL	$0.28 - $0.93 $16,800 - $55,800	-60,000 Reduced 59.11%	41,500 $12,000
Q2 2023 Aug 01, 2023	SELL	$0.55 - $1.26 $56,567 - $129,591	-102,850 Reduced 50.33%	101,500 $71,000
Q1 2023 May 05, 2023	BUY	$0.89 - $2.52 $78,364 - $221,886	88,050 Added 75.71%	204,350 $183,000
Q4 2022 Jan 24, 2023	BUY	$1.02 - $7.48 $53,397 - $391,578	52,350 Added 81.86%	116,300 $0
Q3 2022 Nov 10, 2022	BUY	$6.04 - $9.66 $1,510 - $2,415	250 Added 0.39%	63,950 $482,000
Q2 2022 Aug 11, 2022	BUY	$4.99 - $8.96 $6,986 - $12,544	1,400 Added 2.25%	63,700 $401,000
Q1 2022 Apr 20, 2022	SELL	$3.84 - $9.74 $1,152 - $2,922	-300 Reduced 0.48%	62,300 $517,000
Q4 2021 Feb 02, 2022	BUY	$5.12 - $8.19 $7,424 - $11,875	1,450 Added 2.37%	62,600 $325,000
Q3 2021 Oct 28, 2021	BUY	$6.68 - $9.1 $301,936 - $411,320	45,200 Added 283.39%	61,150 $408,000
Q2 2021 Aug 13, 2021	BUY	$7.82 - $9.23 $5,865 - $6,922	750 Added 4.93%	15,950 $136,000
Q4 2020 Feb 09, 2021	BUY	$7.98 - $12.29 $121,296 - $186,808	15,200 New	15,200 $187,000

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $418M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Sigma Planning Corp, based on Form 13F filings with the SEC.

Stay updated on Sigma Planning Corp with notifications on news.